ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Boehringer Ingelheim will enter the antibody-drug conjugate (ADC) field by acquiring the Swiss firm NBE-Therapeutics for about $1.4 billion. NBE conjugates antibodies to anthracycline-based toxins, which it says are much more potent than the toxins in approved ADCs such as Adcetris and Kadcyla. NBE says it uses enzymatic conjugation to keep toxins tethered to antibodies until they are taken up by tumor cells. Its lead candidate, NBE-002, is in Phase 1 trials.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X